Close Menu

NIPD Genetics

Last month, the Cyprus-based genetic diagnostics company launched a number of hereditary cancer and somatic tumor sequencing panels, its first tests for oncology.

The companies will bring NIPD Genetics' Veracity and Veragene noninvasive prenatal tests to Medicover's markets, as well as developing new genetic tests.

The firm plans to include seven subchromosomal alterations to its NIPT by the end of March and wants to expand into the liquid biopsy market.

The company has also expanded its current Veracity NIPT to sex chromosomal aneuplodies and twin pregnancies, and plans to offer microdeletion testing next year.

The Cyprus-based company recently moved into new premises, increased its headcount, and received CAP accreditation for its laboratory.

The nonprofit Biden Cancer Initiative is suspending its operations, according to the Associated Press.

Researchers examine how white nationalists handle personal genetic ancestry results that conflict with their racist worldview, the New York Times reports.

NPR speaks with research participants before and after they learn their APOE E4 status, which affects their risk of developing Alzheimer's disease.

In PLOS this week: genetic characterization of Toxoplasma gondii strains, Crimean-Congo Hemorrhagic Fever Virus uncovered in Sudan, and more.